During the past 12 months chloroquine and hydroxychloroquine have been touted as cures for COVID-19 and introduced into Covid-19 treatment protocols. This has led to increases in demand, leaving some rheumatoid arthritis and lupus patients deprived of effective treatments.

A newly published Cochrane Library Editorial explores the story of the assessment of chloroquine and hydroxychloroquine efficacy and the lessons learnt. 

This Editorial publishes alongside the recently published review published in the Cochrane Library  that concludes that hydroxychloroquine  has no clinical benefit in treating COVID-19 in hospitalised patients.

View larger sized visual abstract

• Read the Editorial
• Read the Cochrane Review 'Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19'
• Read the Cochrane Clinical Answer 'For adults with coronavirus disease 2019 (COVID‐19), what are the benefits and harms of hydroxychloroquine?'
• Learn more about the visual abstracts created by Emory med students
• Read all the Cochrane resources and news on COVID-19
• Find out more about Cochrane COVID Reviews